Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Total Liabilities (2023 - 2025)

Historic Total Liabilities for Beta Bionics (BBNX) over the last 3 years, with Q3 2025 value amounting to $35.3 million.

  • Beta Bionics' Total Liabilities fell 8458.1% to $35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year decrease of 8458.1%. This contributed to the annual value of $73.6 million for FY2024, which is 4316.38% up from last year.
  • Beta Bionics' Total Liabilities amounted to $35.3 million in Q3 2025, which was down 8458.1% from $28.3 million recorded in Q2 2025.
  • Beta Bionics' Total Liabilities' 5-year high stood at $228.8 million during Q3 2024, with a 5-year trough of $24.3 million in Q1 2025.
  • In the last 3 years, Beta Bionics' Total Liabilities had a median value of $62.5 million in 2023 and averaged $109.7 million.
  • Per our database at Business Quant, Beta Bionics' Total Liabilities surged by 4316.38% in 2024 and then tumbled by 8867.5% in 2025.
  • Beta Bionics' Total Liabilities (Quarter) stood at $51.4 million in 2023, then soared by 43.16% to $73.6 million in 2024, then plummeted by 52.08% to $35.3 million in 2025.
  • Its Total Liabilities stands at $35.3 million for Q3 2025, versus $28.3 million for Q2 2025 and $24.3 million for Q1 2025.